Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

AudioEye Reports Record Second Quarter 2025 Results

Thirty-Eighth Consecutive Period of Record Revenue TUCSON, Ariz., Aug. 7, 2025 /PRNewswire/ -- AudioEye, Inc. (Nasdaq: AEYE) ("AudioEye" or the "Company"), the industry-leading digital accessibilit...

What are the subscription renewal rates or customer retention metrics for the quarter, and how might they impact future revenue growth? What risks or headwinds could threaten the continuation of the 38‑period record‑revenue streak? What short‑term price momentum can be expected based on the earnings surprise and record revenue narrative?
Symbol: AEYE
Earnings
21 days ago
Read more prnewswire

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

$60.0M in 2Q25 Total Product Revenue

What potential catalysts or risks could cause the stock to move significantly after this earnings release? How might the market’s sentiment score of 70 influence short‑term trading activity and volatility? What is the company’s cash position and burn rate relative to the reported revenue, and does it raise any liquidity concerns?
Symbol: IOV
Earnings
21 days ago
Read more globenewswire

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

WATERTOWN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of ther...

Will the recent business highlights affect the company's valuation multiples (P/E, price-to-sales, EV/EBITDA) relative to comparable biotech companies? What is the market's reaction to the announcement (intraday price movement, volume) and how does it compare to the industry average? How does the sentiment score (20) reflect market sentiment, and does it suggest a potential mispricing?
Symbol: TECX
Earnings
21 days ago
Read more globenewswire

Ascendis Pharma Reports Second Quarter 2025 Financial Results

– Q2 2025 revenue of €103.0 million for YORVIPATH¼ and €50.7 million for SKYTROFA¼

How does ASC's Q2 performance compare to peer companies in the same therapeutic area? Is there any information on the pipeline or upcoming regulatory milestones that could influence future earnings? What are the key drivers behind the revenue performance—price changes, volume growth, or new product launches?
Symbol: ASC
Earnings
21 days ago
Read more globenewswire

Apyx Medical Corporation Reports Second Quarter 2025 Financial Results

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency plat...

How might the reported results influence analyst sentiment and target price revisions for APYX in the near term? Did the company disclose any strategic partnerships, licensing agreements, or M&A activity that could affect its growth trajectory? What competitive pressures or market dynamics are influencing Apyx Medical's performance relative to peers in the minimally invasive device space?
Symbol: APYX
Earnings
21 days ago
Read more globenewswire

Turtle Beach Corporation Announces Second Quarter 2025 Financial Results and Reiterates Full Year Guidance

–Delivered Net Revenue of $56.8 Million– –Gross Margin Improved to 32.2%, an Increase of 200 Basis Points Compared to Prior Year– –Net Loss of $2.9 Million Compared to Net Loss of $7.5 Million in P...

How does Turtle Beach's performance this quarter compare to the broader industry trends in gaming hardware and peripheral demand? What are the risks to the full‑year guidance if macro‑economic conditions or consumer demand for gaming accessories shift? How might the Q2 results influence short‑term technical patterns and volume activity for TBCC stock?
Symbol: TBCC
Earnings
21 days ago
Read more globenewswire

Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025

PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the su...

Will there be any changes to the company's capital allocation or R&D spending plans following the Investor Day? What are the potential risks or challenges highlighted for the commercialization of the new products? How might the Investor Day affect short‑term stock price volatility and trading volume?
Symbol: TMCI
Events
21 days ago
Read more globenewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as e...

How could the market react to the sentiment score of 65 in the context of broader sector sentiment? What risks remain for the drug's development despite the encouraging cohort 3 results? How might this data influence partnership or licensing opportunities with larger pharmaceutical companies?
Symbol: CRVS
Clinical
21 days ago
Read more globenewswire